

## Assessing the stereoselectivity of *Serratia marcescens* CECT 977 2,3-butanediol dehydrogenase

Medici, Rosario; Stammes, Hanna; Otten, Linda G.; Hanefeld, Ulf; Kwakernaak, Stender

**DOI**

[10.1039/c7cy00169j](https://doi.org/10.1039/c7cy00169j)

**Publication date**

2017

**Document Version**

Final published version

**Published in**

Catalysis Science & Technology

**Citation (APA)**

Medici, R., Stammes, H., Otten, L. G., Hanefeld, U., & Kwakernaak, S. (2017). Assessing the stereoselectivity of *Serratia marcescens* CECT 977 2,3-butanediol dehydrogenase. *Catalysis Science & Technology*, 7(9), 1831-1837. <https://doi.org/10.1039/c7cy00169j>

**Important note**

To cite this publication, please use the final published version (if applicable). Please check the document version above.

**Copyright**

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

**Takedown policy**

Please contact us and provide details if you believe this document breaches copyrights. We will remove access to the work immediately and investigate your claim.



Cite this: *Catal. Sci. Technol.*, 2017, 7, 1831

## Assessing the stereoselectivity of *Serratia marcescens* CECT 977 2,3-butanediol dehydrogenase<sup>†‡</sup>

Rosario Mé dici, Hanna Stammes, Stender Kwakernaak, Linda G. Otten and Ulf Hanefeld\*

$\alpha$ -Hydroxy ketones and vicinal diols constitute well-known building blocks in organic synthesis. Here we describe one enzyme that enables the enantioselective synthesis of both building blocks starting from diketones. The enzyme 2,3-butanediol dehydrogenase (BudC) from *S. marcescens* CECT 977 belongs to the NADH-dependent metal-independent short-chain dehydrogenases/reductases family (SDR) and catalyses the selective asymmetric reductions of prochiral  $\alpha$ -diketones to the corresponding  $\alpha$ -hydroxy ketones and diols. BudC is highly active towards structurally diverse diketones in combination with nicotinamide cofactor regeneration systems. Aliphatic diketones, cyclic diketones and alkyl phenyl diketones are well accepted, whereas their derivatives possessing two bulky groups are not converted. In the reverse reaction vicinal diols are preferred over other substrates with hydroxy/keto groups in non-vicinal positions.

Received 25th January 2017,  
Accepted 22nd February 2017

DOI: 10.1039/c7cy00169j


rsc.li/catalysis

### 1. Introduction

Enantiomerically pure  $\alpha$ -hydroxy ketones and vicinal diols constitute a valuable group of molecules useful directly as fine chemicals or as building blocks for asymmetric synthesis of bioactive compounds and agrochemicals.<sup>1,2</sup> Numerous chemical and enzymatic strategies have been devised to address this challenge.<sup>2</sup> To date all chemical approaches<sup>3–5</sup> and most of the biochemical approaches<sup>6–8</sup> only allow the formation of one of the two chiral products: either the  $\alpha$ -hydroxy ketones or vicinal diols. A particular challenge is the development of methodologies allowing for the targeted selective synthesis of both  $\alpha$ -hydroxy ketones and vicinal diols, in particular with aliphatic side chains (Scheme 1).

Acetoin reductases/2,3-butanediol dehydrogenases (EC 1.1.1.4 and 1.1.1.76) constitute a less explored group of enzymes. They belong to the family of NADH-dependent metal-independent short-chain dehydrogenases/reductases and are responsible for the accumulation of 2,3-butanediols in high titers ( $>100 \text{ g L}^{-1}$ ) during the cultivations of species such as *Klebsiella*, *Enterobacter*, *Serratia* and *Bacillus*.<sup>9</sup> In general, 2,3-butanediol is not produced as a single isomer, but as a mixture of *meso*-2,3-butanediol with (*S,S*)-butanediol (*L*-(+)-form)

or (*R,R*)-2,3-butanediol (*D*-(-)-form). Microorganisms that do not produce the *meso* diol, generate optically enriched (*R,R*)-butanediol. The variations in optical purity might be due to a single unselective enzyme or due to mixtures of selective enzymes. In particular, the *Bacillus stearothermophilus*<sup>10</sup> enzyme (2*S,3S*)-2,3-butanediol dehydrogenase (BDH, EC 1.1.1.76) gave excellent enantioselectivities for a range of substrates towards the *S,S*-diols. *R,R*-Diols could be obtained employing for instance *Saccharomyces cerevisiae* BDH.<sup>11</sup> This indicates that more enzymes with similarly high specificities for other



**Scheme 1** Summary of enzymatic methods applied for the synthesis of  $\alpha$ -hydroxy ketones and vicinal diols, employing oxidoreductases,<sup>7,12–14</sup> lyases,<sup>15,16</sup> hydrolases<sup>17</sup> and epoxide hydrolases.<sup>18</sup> Double reduction of  $\alpha$ -diketones is achieved by a few oxidoreductases<sup>19–22</sup> and enzymatic cascade strategies involving two enzymatic steps.<sup>8,23,24</sup>

*Biokatalyse, Afdeling Biotechnologie, Technische Universiteit Delft, van der Maasweg 9, 2629 HZ Delft, The Netherlands. E-mail: U.Hanefeld@tudelft.nl; Tel: +31 15 2789304*

<sup>†</sup> Dedicated to W. R. “Fred” Hagen on the occasion of his retirement.

<sup>‡</sup> Electronic supplementary information (ESI) available: Chemicals, strains and plasmids, analytical methods; and additional figures. See DOI: 10.1039/c7cy00169j



substrates and isomers including the *meso* isomer should be available. The oxidation of the *meso* isomer would be of particular interest. In principle, this enzymatic transformation could afford enantio-enriched  $\alpha$ -hydroxy ketones with up to 100% yield rather than the 50% obtained through a kinetic resolution approach.

Here we describe the investigation of *meso*-2,3-butanediol dehydrogenase (BudC) from *Serratia marcescens* CECT 977, including its stereoselectivity and substrate range.

## 2. Results and discussion

### 2.1 Cloning and heterologous expression of BudC

In the present work, the *budC* gene encoding to a 2,3-BDH from *S. marcescens* CECT 977 (756 bp) was amplified from genomic DNA and cloned into pET-28a in frame with the N-terminal His<sub>6</sub>-tag to facilitate purification of the recombinant enzyme. The DNA sequence exhibited a 91.8% identity with *S. marcescens* H30 strain<sup>25</sup> and both proteins were identical at protein level. This means that the production and purification described earlier<sup>25</sup> is also valid for the enzyme described here. We therefore concentrated on substrate range and enantioselectivity.

### 2.2 Enzyme kinetics

The *budC* gene was successfully expressed in *E. coli* BL21 (DE3) star cells and the enzyme was purified from *E. coli* cell-free extracts by Ni-NTA affinity chromatography. Activity of crude extracts reached 14.4 U mg<sup>-1</sup> using *rac*-acetoin (50 mM) as substrate at pH 7.0 in a reductive assay (ESI† Fig. S1). SDS-PAGE gels revealed the production of a protein of approximately 28 kDa in agreement with the calculated molecular weight (28.4 kDa). Native gels confirmed the tetrameric oligomerization state, yielding a band between 120–140 kDa (ESI† Fig. S2) in line with the earlier results.<sup>25</sup>

BudC catalyses the reduction of *rac*-acetoin preferably at weakly acidic pH 5.0 rather than neutral pH (975 U mg<sup>-1</sup> vs. 250 U mg<sup>-1</sup>). However, kinetic parameters at pH 5.0 were difficult to determine, yielding inconsistent data due to the low stability of the enzyme at this pH ( $t_{1/2}$ : 2.5 h, Fig. 1).

In line with these observations, only kinetic parameters at pH 7.0 were determined (Table 1, ESI† Fig. S4, A–D). In the




Fig. 1 Effect of the temperature and pH on BudC activity. Reaction conditions: 0.16 mM NADH, 0.27 nM BudC, 50 mM *rac*-acetoin in potassium phosphate buffer (50 mM, pH 7.0) or potassium acetate buffer (50 mM, pH 5.0) at the corresponding temperatures.

Table 1 Kinetic data of purified BudC<sup>a</sup>

Substrate	$V_{\max}$ (U mg <sup>-1</sup> )	$K_m$ (mM)	$k_{\text{cat}}$ (s <sup>-1</sup> )	$k_{\text{cat}}/K_m$ (M <sup>-1</sup> s <sup>-1</sup> )
<i>meso</i> -2,3-BDO <sup>b</sup>	140.7 ± 5.2	6.9 ± 1	66.6	9.6 × 10 <sup>3</sup>
Diacetyl <sup>c</sup>	412 ± 11.0	1.7 ± 0.2	195.0	1.1 × 10 <sup>5</sup>
(±)-Acetoin <sup>c</sup>	250.8 ± 3.1	3.1 ± 0.3	118.7	3.8 × 10 <sup>4</sup>
(2 <i>S</i> ,3 <i>S</i> )-2,3-BDO <sup>b</sup>	—	—	—	—
(2 <i>R</i> ,3 <i>R</i> )-2,3-BDO <sup>b</sup>	—	—	—	—

<sup>a</sup> Reaction conditions: 0.16 mM/0.32 mM NADH/NAD<sup>+</sup>, 0.27 nM BudC, substrate concentration 100 μM to 150 mM in potassium phosphate buffer (50 mM, pH 7.0) at 37 °C. Turnover numbers ( $k_{\text{cat}}$ ) are expressed per monomer of BudC. <sup>b</sup> Oxidation reaction. <sup>c</sup> Reduction reaction.

reductive reaction diacetyl is the preferred substrate of BudC over acetoin, while only *meso*-2,3-butanediol oxidation was catalysed by the enzyme under the conditions assessed. Despite its protein sequence identity with the enzyme from *S. marcescens* H30, the specific activities obtained in our study with BudC were significant higher than those reported earlier (up to 4.5-fold at pH 5.0)<sup>25</sup> under identical reaction conditions.

### 2.3 Bioconversions

When reduction reactions containing stoichiometric amounts of substrate (diacetyl or acetoin), NADH (5 mM) and BudC (0.5 μM) were performed, no product formation was observed in any case. Variation of the NADH concentration revealed this to be due to NADH inhibition. Although not previously reported for this enzyme, NADH inhibition was observed at concentrations higher than 0.3 mM; 1 mM being sufficient for complete inhibition (ESI† Fig. S5).

Consistent with the previous results, nicotinamide cofactor regeneration strategies are essential to achieve significant product yields. Ethanol, 2-propanol, and acetone were tested as co-substrates for *substrate-coupled* cofactor regeneration. However, none of them was accepted by BudC (Table 2). An *enzyme-coupled* approach was accomplished employing formate dehydrogenase and glucose dehydrogenase (both as crude cell extracts) to recycle NADH, and NADH oxidase (as crude cell extracts) to regenerate NAD<sup>+</sup>. With these systems at hand, both the BudC catalysed oxidation and reduction could be investigated.

Whereas BudC was *S*-selective for the reduction of diacetyl yielding (*S,S*)-2,3-butanediol ((*S,S*)-2,3-BDO), *rac*-acetoin was reduced to both *meso*-2,3-BDO and (*S,S*)-2,3-BDO. Here (*R*)-acetoin was the preferred substrate and 15% (*S*)-acetoin remained unconverted after 24 h. Thus, BudC showed a stereo-preference consistent with *meso*-2,3-butanediol dehydrogenases with respect to acetoin.

In the oxidation reaction *meso*-2,3-BDO led to a complex product mixture. Starting with the initial formation of (*R*)-acetoin BudC catalysed its racemization within 24 h, concomitant with oxidation and reduction reactions, yielded small amounts of (2*S*,3*S*)-2,3-BDO as a side product.



**Table 2** Substrate scope of BudC from *S. marcescens* CECT 977<sup>a</sup>

Compound	U mg <sup>-1</sup>
<b>1a</b> 2,3-pentanedione	249.2 ± 11.4
<b>1b</b> 2,3-hexanedione	220.5 ± 12.6
<b>1c</b> 3,4-hexanedione	88.5 ± 2.1
<b>1d</b> 2,3-heptanedione	19.4.6 ± 0.7
<b>1e</b> 1-phenyl-1,2-propanedione	23.4 ± 3.4
<b>1f</b> 1,2-cyclohexanedione	6.2 ± 0.5
<i>R</i> -Benzoin	n.d. <sup>b</sup>
<i>rac</i> -Benzoin	n.d.
Benzil	n.d.
Acetone	n.d.
2,4-Pentandiol	<1.0
1,3-Butanediol	<1.0
Ethanol	n.d.
2-Propanol	n.d.


<sup>a</sup> Reaction conditions: 50 mM substrate, 0.16 mM/0.32 mM NADH/NAD<sup>+</sup>, 0.27 nM BudC in potassium phosphate buffer (50 mM, pH 7.0) at 37 °C. Experiments were performed in triplicate and the data are presented as means with standard deviations. <sup>b</sup> n.d.: not detected.

In agreement with the kinetic measurements (Table 1), (2*S*,3*S*)-2,3-BDO was poorly converted to (*S*)-acetoin (<5% yield). No measurable amounts of diacetyl were detected.

Overall, BudC is *S*-selective for the reduction reaction of diacetyl to (2*S*,3*S*)-2,3-BDO but displays a preference for (*R*)-acetoin as a substrate for the second reduction step, which is also reduced with *S*-selectivity. In the reverse oxidation reaction *meso*-2,3-BDO was converted under the tested conditions, while the other diols and acetoin are poor substrates for the oxidation reaction (Scheme 2).

#### 2.4 Substrate scope

In order to broaden the applicability of BudC, we extended our investigation to structurally diverse  $\alpha$ -diketones and *vic*-diols. Enzymatic activity was determined spectrophotometrically and the results are presented in Table 2. In the reduction reaction 2,3-diketones were good substrates of BudC,



**Scheme 2** Specificity of BudC in the reduction and oxidation of 2,3-dioxygenated butane.

while the enzyme activity decreases with the increase of alkyl chain length. Sterically more demanding ketone moieties, such as 1,2-cyclohexanedione and 1-phenyl-1,2-propanedione were also converted by BudC, while bulky-bulky  $\alpha$ -diketones, such as benzil, or  $\alpha$ -hydroxy ketones (*i.e.* benzoin) were not converted. Thus, BudC catalyses the reduction of aliphatic symmetric and non-symmetric  $\alpha$ -diketones, while its activity is severely affected by the presence of bulky moieties next to the carbonyl groups either due to steric hindrance (*i.e.* **1c**, **1d** and **1e**) or conformational effects (**1c** and **1f**).

In the oxidation reaction non-vicinal diols such as 2,4-pentandiol and 1,3-butanediol were no substrates of BudC. These results are in agreement with those previously reported by Zhang *et al.*<sup>25</sup> indicating that vicinal diols (1,2-, 2,3- or 3,4) are required for catalysis.


#### 2.5 Analysis of BudC stereoselectivity

The reduction of compounds **1a–1f** was further investigated employing both NADH regeneration systems using formate dehydrogenase or glucose dehydrogenase, depending the reaction scale (Fig. 2 and Scheme 3).

Reaction products were isolated by column chromatography and characterised by <sup>1</sup>H and <sup>13</sup>C NMR, optical rotation, and by comparison with the products obtained under the same conditions with a well characterised commercial enzyme ADH-380 (Evoxx, Düsseldorf, Germany), which is known to yield the corresponding *S*-stereoisomers. Moreover, ADH-380 catalysed reactions were used as positive control.<sup>26</sup> Slight differences in reaction yields and stereoselectivities were observed depending on the regeneration system employed (crude extracts of formate or glucose dehydrogenase).


2,3-Pentanedione (**1a**) was reduced to the diol (2*S*,3*S*)-**4a** in good yield and selectivity after 1 h. After 24 h the yield was improved further but a slight loss of selectivity was observed (Table 3, entry 1–2, ESI<sup>†</sup> Fig. S7 and S11). The results are in line with those for diacetyl (Scheme 2).

2,3-Hexanedione (**1b**) was also rapidly reduced to the corresponding  $\alpha$ -hydroxy ketone, with (*S*)-3-hydroxy-2-hexanone (**3b**) as the main reaction product (80% yield, 99% ee, Table 3, entry 4), while 2,3-hexanediol was produced only in low yields. High yields of **3b** were also achieved at *semi*-preparative scale with a minor loss of enantioselectivity (Table 3, entry 5, ESI<sup>†</sup> Fig. S8 and S12). It should be noted



**Fig. 2**  $\alpha$ -Diketones reduced by BudC.





**Scheme 3** Stereoselective reduction of 1,2-diketones using BudC from *S. marcescens* CECT 977.

that the less accessible 3-ketogroup was selectively reduced and the reaction almost stopped completely after a single reduction. The second reduction step was much slower, allowing to selective production of the acyloin.

A modified reaction profile was observed with 2,3-heptanedione (**1d**). A mixture of 2-hydroxy-3-heptanone (**2d**) and 3-hydroxy-2-heptanone (**3d**) was produced, the latter again as the main reaction product (Table 3, entries 9–10). As with **1b** the less accessible 3-ketogroup was thus reduced preferably. Despite extensive efforts, the regio-isomers could not be separated by column chromatography; therefore the absolute stereochemistry of **3d** could not be determined (ESI† Fig. S10 and S15–S17). Based on the other results it can tentatively be assigned as (*S*). (2*S*,3*R*)-2,3-Heptanediol (**4d**) was obtained in low yields (<5%). Neither longer reaction times nor fresh pulses of the enzyme improved the yield of the diol.

In contrast to other dehydrogenases (*i.e.*, ADH-A from *Rhodococcus ruber* or ADH-T from *Thermoanaerobacter* sp.),<sup>19,20</sup> where the extension of  $\alpha$ -diketone alkyl chain ( $n = 1$  to  $n = 3$ ) increased the selectivity of the enzymes, a lower regio-selectivity was observed in case of budC, indicating its preference for small substrates.

The reduction of 3,4-hexanedione (**1c**) proceeded with the same stereoselectivity as for diacetyl, (*S*)-acetoin and **1a** yielding (3*S*,4*S*)-3,4-hexanediol (**4c**) (79% yield, 92% stereoselectivity). When higher substrate concentrations were employed and the reaction time shortened (Table 3, entries 7), (*S*)-4-hydroxy-3-hexanone (**2c**) was produced with excellent yields (92%) and stereoselectivity (93% ee). This supports the stereochemical assignment of **3d** (ESI† Fig. S8, S13 and S14).

1-Phenyl-1,2-propanedione reduction yielded (*S*)-2-hydroxy-1-phenylpropan-1-one (**3e**) as the main product (55% yield, 89% ee), (*S*)-1-hydroxy-1-phenylpropan-2-one (**2e**, 25% yield, 85% ee) and (*S,S*)-1-phenyl-1,2-propanediol (**4e**) (9% yield, 99% ee, 59% de) (Table 3, entry 14, ESI† Fig. S6). Longer incubation times increased the yield of **4e** up to 30%, but reduced the stereoselectivity (Table 3, entry 15). While the *S*-selectivity was maintained BudC surprisingly cannot differentiate between a methyl and a phenyl-group.

1,2-Cyclohexanedione was completely reduced to (*S,S*)-1,2-cyclohexanediol (**4f**) in good yields (66%) and with excellent ee (99%) although poorer de (67%), as *cis*-1,2-cyclohexanediol was also detected as a reaction product. It could not be distinguished whether the low de was due to poor selectivity in the first or second reduction step.

## 2.6 Homology modelling of BudC and substrate docking

An homology model of BudC was made based solely on the structure of the *meso*-2,3-BDH from *Klebsiella pneumoniae* (*Kp*BDH, PDB 1GEG).<sup>27</sup> This resulted in a model in which the positioning of several active site residues is in line with another *meso*-BDH, which seems important for the enantioselectivity of the enzyme.<sup>28</sup> The model shows the enzyme as a


**Table 3** Biocatalytic reduction of  $\alpha$ -diketones with BudC and ADH-380 and NADH regeneration systems<sup>a</sup>

Entry	Substrate	Conc. [mM]	Enzyme	Reg. syst.	2 <sup>b</sup> [%]	ee <sup>b</sup> [%]	3 [%]	ee [%]	4 [%]	de [%]	ee [%]	Time (h)
1	<b>1a</b>	10	BudC	FDH	—	—	—	—	71	(2 <i>S</i> ,3 <i>S</i> )	96 <sup>c</sup>	1
2	<b>1a</b>	10	BudC	FDH	—	—	—	—	90	(2 <i>S</i> ,3 <i>S</i> )	94 <sup>c</sup>	24
3	<b>1a</b>	10	ADH-380	FDH	—	—	—	—	92	99 (2 <i>S</i> ,3 <i>S</i> )	>99	24
4	<b>1b</b>	10	BudC	FDH	<5	ND	80	99	<5	ND	—	24
5	<b>1b</b>	50	BudC	GDH	—	—	90	96	<5	ND	—	48
6	<b>1c</b>	10	BudC	FDH	15	80 ( <i>S</i> )	—	—	79	(2 <i>S</i> ,3 <i>S</i> )	92 <sup>c</sup>	24
7	<b>1c</b>	50	BudC	GDH	92	93 ( <i>S</i> )	—	—	<5	ND	—	1
8	<b>1c</b>	10	ADH-380	FDH	—	—	—	—	99	99 (2 <i>S</i> ,3 <i>S</i> )	99	24
9	<b>1d</b>	10	BudC	FDH	31	91 ( <i>S</i> )	57	99 (ND)	<5	ND	—	24
10	<b>1d</b>	10	BudC	GDH	46	97 ( <i>S</i> )	40	99 (ND)	<5	ND	—	24
11	<b>1d</b>	50	BudC	GDH	20	89 ( <i>S</i> )	68	99 (ND)	<5	ND	—	48
12	<b>1d</b>	10	ADH-380	FDH	29	99 ( <i>S</i> )	—	—	65	(2 <i>S</i> ,3 <i>R</i> )	94 <sup>c</sup>	24
13	<b>1d</b>	10	ADH-380	GDH	<5	ND	—	—	95	99 (2 <i>S</i> ,3 <i>R</i> )	99	24
14	<b>1e</b>	10	BudC	FDH	25	85 ( <i>S</i> )	55	89 ( <i>S</i> )	9	59 (1 <i>S</i> ,2 <i>S</i> )	99	2
15	<b>1e</b>	10	BudC	FDH	15	85 ( <i>S</i> )	40	83 ( <i>S</i> )	30	5 (1 <i>S</i> ,2 <i>S</i> )	99	24
16	<b>1e</b>	10	ADH-380	FDH	<5	ND	65	99 ( <i>S</i> )	36	69 (1 <i>S</i> ,2 <i>S</i> )	99	24
17	<b>1f</b>	10	BudC	FDH	—	—	—	—	66	67 (1 <i>S</i> ,2 <i>S</i> )	99 (1 <i>S</i> ,2 <i>S</i> )	2
18	<b>1f</b>	10	BudC	FDH	—	—	—	—	66	67 (1 <i>S</i> ,2 <i>S</i> )	99	24
19	<b>1f</b>	10	ADH-380	FDH	—	—	—	—	81	99 (1 <i>S</i> ,2 <i>S</i> )	99	24

ND stands for not determined. <sup>a</sup> Reaction conditions: the corresponding diketone (**1a–1f**, 10 or 50 mM) was added to 50 mM potassium phosphate buffer pH 7.0 with the nicotinamide cofactor (0.16 mM), BudC (2 U ml<sup>-1</sup>) and regeneration system (FDH or GDH, 2 U ml<sup>-1</sup>). <sup>b</sup> Yields, ees and des were determined by chiral GC analysis (when possible). <sup>c</sup> Small peaks could not be assigned due to missing standards, therefore it was impossible to distinguish between ee and de.







**Fig. 3** Homology model of BudC based on *meso*-2,3-butanediol dehydrogenase from *K. pneumoniae* (1GEG). The substrate diacetyl (blue sticks) was modelled based on the co-crystallised beta-mercaptoethanol in 1GEG. Tyr155 and Ser138 (yellow) are both hydrogen bonded to the proximal keto-group. The Tyr donates a hydride to the oxygen of the substrate, while the pro-*R* hydride from NADH (orange) transfers to the carbon, resulting in the *S*-configuration of the hydroxyl group.

tetramer, which is in accordance with the results from the native PAGE and other SDR family members (see ESI† Fig. S18 and S19). The important active site residues for SDRs (Asn-Ser-Tyr-Lys) are in the exact same position as in other BDHs, the only difference is Asp111 in the place where normally an Asn is located. This residue plays an essential role in keeping the conformation of the active site and allowing a proton relay system,<sup>29</sup> which is still there involving the Asp residue.

Docking different substrates and products did not result in good binding poses. This is probably due to the small nature of the substrates. This was confirmed by the fact that docking these small compounds into the crystal structure of the *Kp*BDH also did not result in proper binding modes. Furthermore, the loop just outside the binding pocket is probably moving upon binding of the substrate which cannot be mimicked by the docking *in silico*.

Normally the reduction of the proximal keto group results in the *S*-enantiomer of the corresponding  $\alpha$ -hydroxy ketone. The pro-*R* NADH hydride transfer from NADH to the *re*-face of diketones yields (*S*)-hydroxy ketones, indicating that the enzyme obeys canonical Prelog addition (Fig. 3). Small diketones are most probably fixed at the correct distance to NADH with hydrogen bonds, similar to *Kp*BDH. Since the active site easily can accommodate larger substrates, the larger and more aliphatic penta-, hexa- and heptadione can bind into the active site in an alternative orientation. In this way the 3-keto group may be positioned properly towards the NADH, resulting in the respective 3*S*-hydroxyketone. Reduced affinity of this alternative binding mode can explain the decreased activity for the larger substrates.

### 3. Conclusions

The BudC gene was successfully cloned and recombinantly expressed in *E. coli*. The enzyme is (*S*)-selective for all tested substrates and has a broad substrate scope. Unlike other

ADHs it displays a better stereoselectivity for smaller substrates. Although the enzyme is strictly *S*-specific for all small substrates, *meso*-2,3-BDO is produced with excellent selectivity using *Serratia marcescens* strains. The production of this compound can be explained by the accumulation of *R*-acetoin in these strains, which is a very good substrate for the *S*-specific BudC.

By varying reaction conditions, single or double reductions as well as oxidations could be achieved in one step. This makes this enzyme an outstanding biocatalyst for the synthesis of different chiral compounds from prochiral diketones and diols.

## 4. Experimental

### 4.1 Strains, plasmids and culture conditions

All standard recombinant DNA procedures were performed as described by Sambrook *et al.*<sup>30</sup> The host strains *Escherichia coli* DH5 $\alpha$  (Thermo Fisher Scientific, Breda, The Netherlands) and *Escherichia coli* BL21 star (DE3) (Thermo Fisher Scientific) were used in sub-cloning and expression experiments, respectively.

*Serratia marcescens* CECT 977 was supplied by the Spanish Type Culture Collection (CECT, University of Valencia, Spain) and as DNA source for *budC* cloning. pGEMT-easy (Promega, Promega Benelux B.V., Leiden, The Netherlands) was used as cloning vector and pET-28a (Merck Millipore, Amsterdam, The Netherlands) as expression vector.

Bacteria were routinely grown at 37 °C in liquid Luria-Bertani broth medium (NaCl, 5 g L<sup>-1</sup>; tryptone, 10 g L<sup>-1</sup>; yeast extract, 5 g L<sup>-1</sup>) containing 100  $\mu$ g ml<sup>-1</sup> ampicillin or 50  $\mu$ g ml<sup>-1</sup> kanamycin when required.

### 4.2 Construction of pET-28a *budC* expression vector

*S. marcescens* genomic DNA was extracted following a standard phenol/chloroform procedure as reported by Sambrook *et al.*<sup>30</sup> A *budC* consensus sequence was generated



based on the alignment of homologous sequences from five *S. marcescens* strains (*S. marcescens* SM39, accession number: AP013063; *S. marcescens* MG1, accession number: JF519738; *S. marcescens* subsp. *marcescens* Db11, accession number HG326223; *S. marcescens* G12, accession number: KF547938; *S. marcescens* WW4, accession number: CP003959) with *budC* gene sequence of *S. marcescens* H30 (accession number: JQ63959) reported by Zhang *et al.*,<sup>25</sup> as template.

The *budC* gene was PCR amplified from *S. marcescens* CECT 977 genomic DNA using the forward 5'-GGAATTCATATGCGTTTTGACAATAAAGTCGTGGTTATC -3' (*Nde*I site in bold) and reverse primer 5'-CGCTCGAGTTAGACGATCTTCGGTTGGCCGTCCGA-3' (*Xho*I site in bold). The PCR was performed using Accuprime *Pfx* DNA polymerase (Thermo Fisher Scientific) with the following conditions: 0.1 µg of chromosomal DNA, 0.3 µM of each primer, 5 µl of 10× *Pfx* reaction mix and 2.5 units of *Pfx* DNA polymerase in a final volume of 50 µl. A hot start of 2 minutes at 95 °C was followed by 30 cycles of denaturation (15 s at 95 °C), annealing (30 s at 56 °C), and extension (1 min at 68 °C). The PCR product was first purified using a Gel purification kit (Qiagen, Venlo, The Netherlands), followed by an A-tailing procedure with *Taq* DNA polymerase (Qiagen).

*BudC* gene was ligated into pGEM® T-Easy vector system (Promega, Leiden, The Netherlands), and the resulting plasmids were produced in *E. coli* DH5α. The resulting constructs were confirmed by DNA sequencing, restricted with *Nde*I and *Xho*I, and the coding gene was ligated into the corresponding sites of pET-28a vector (Merck Millipore, Amsterdam, The Netherlands), introducing a (His)<sub>6</sub>-tag at the N-terminus of *budC* gene product.

Recombinant expression of *budC* was performed using *E. coli* BL21 star (DE3) cells transformed with pET-28a-*budC* in autoinduction media (ZYM-5052)<sup>31</sup> supplemented with 100 µg ml<sup>-1</sup> of kanamycin at 22 °C and 150 rpm during 24 h. Cells were harvested by centrifugation at 12 500 × *g* for 15 minutes at 4 °C, washed twice with potassium phosphate buffer (50 mM, pH 7.0), re-centrifuged stored at -80 °C until further use.

### 4.3 BudC purification

Cell-free extracts (CFE) were obtained incubating first the cells in binding buffer (sodium phosphate 50 mM, 300 mM NaCl, 20 mM imidazole, pH 8.0) containing egg white lysozyme (1 mg ml<sup>-1</sup>) and DNase I (0.1 mg ml<sup>-1</sup>) for 1 h at 4 °C, followed by 2 cycles of cell disruption (French Press, 1.5 kBar) and finally centrifuged at 12 500 × *g* and 4 °C for 45 min. CFE was filtered through 0.45 µm filter and applied onto a 5 ml Ni-NTA HisTrap HP column (GE Healthcare Life Sciences, Eindhoven, The Netherlands) previously equilibrated with binding buffer. An imidazole gradient was then applied (20 mM–500 mM imidazole, 3 ml min<sup>-1</sup>, 60 minutes) and *BudC* was eluted with about 350 mM of imidazole.

Enzyme fractions were analysed by SDS-PAGE (12% Bis-Tris gels, Bio-Rad, Munich, Germany). Fractions containing

*BudC* were combined, concentrated by centrifugation using an Amicon filter (10 kDa, Merck Millipore) and applied onto a PD-10 desalting column (Thermo Fischer Scientific) previously equilibrated with 50 mM potassium phosphate, pH 7.0. Enzyme aliquots were frozen in liquid nitrogen and stored at -80 °C. Protein concentration was determined by the bicinchoninic acid assay (Interchim Uptima BC assay, Interchim, Montluçon France) using bovine serum albumin (Bio-Rad, Veenendaal, The Netherlands) as standard.

### 4.4 Enzyme kinetics

Enzymatic activity was determined spectrophotometrically by monitoring NADH consumption (oxidation) or formation (reduction) at 340 nm and 37 °C using an extinction coefficient of 6.22 mM<sup>-1</sup> cm<sup>-1</sup>. One unit of activity was defined as the amount of enzyme catalysing the oxidation/reduction of 1 µmol of nicotinamide cofactor per minute under standard conditions (pH 7.0, 37 °C).

Specific activities were measured in potassium phosphate buffer (50 mM, pH 7.0, 1 ml) in presence of 50 mM of substrate and 0.16 mM NADH or 0.32 mM NAD<sup>+</sup>. DMSO (5% (v/v)) was added as a co-solvent to improve the solubility of benzil and benzoin. Reactions were started by addition of the enzyme solution and measured for 3 min. Activities of the CFE was determined using *E. coli* BL21 (DE3) star pET28(a)-*buC* or *E. coli* BL21 (DE3) star pET28(a) as negative control.

Kinetics parameters were investigated using 0.27 nM enzyme in presence of varying substrate (0.01–200 mM) or nicotinamide cofactor concentrations (12.5 µM to 5 mM) at 37 °C. Data were fitted to the Michaelis–Menten equation (non-linear regression, SigmaPlot 8.0) to estimates of *K<sub>m</sub>* and *k<sub>cat</sub>*.

### 4.5 Standard reaction conditions

The standard reduction mixture consisted of 10 mM diketones, 0.16 mM of NADH, 2 U ml<sup>-1</sup> of *BudC* in potassium phosphate buffer (50 mM, pH 7.0) and NADH-regeneration system containing 100 mM ammonium formate and 2 U ml<sup>-1</sup> formate dehydrogenase (Prozomix, Northumberland, UK). Oxidation reactions comprised: 10 mM diols, 0.32 mM NAD<sup>+</sup>, 2 U ml<sup>-1</sup> of *BudC* in potassium phosphate buffer (50 mM, pH 7.0) and NAD<sup>+</sup>-regeneration system containing 4 U ml<sup>-1</sup> of NADH-oxidase (Prozomix).

Reactions were incubated at 37 °C and 600 rpm during 24 h. Aliquots (1 ml) were taken at different reaction times, centrifuged at 13 000 rpm for 2 minutes and supernatants were first saturated with a NaCl saturated solution (0.1 ml) followed by extraction with ethyl acetate (containing isoamyl alcohol as internal standard) (0.5 mL × 2). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and analysed with chiral GC with respect to yield, chemoselectivity and ee (see ESI†).

Aliphatic α-hydroxy ketones and diol standards were obtained carrying out the reduction reactions at 50 ml scale. The reaction mixture contained 50 mM substrate (200 mg 2,3-pentanedione, 285 mg 2,3-hexanedione, 285 mg 3,4-hexanedione, 320 mg 2,3-heptanedione), 7.1 mg NADH, 1.5 g



glucose-1-monohydrate, 0.75 g calcium carbonate, 2 mg glucose dehydrogenase and 2 mg ADH-380 (Evovx) or 1.4 mg of BudC in potassium phosphate buffer (50 mM, pH 7.0). Reaction vessels were incubated at 37 °C and 100 rpm during 24 or 48 h.  $\alpha$ -Hydroxy ketones and diols were purified by column chromatography as detailed in ESI† (sections 3 and 4), characterised by their optical rotation,  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra and compared with authentic standards or literature data when available (see ESI† Fig. S6 to S11).

#### 4.6 Homology modelling of BudC and docking of substrates

An homology model of BudC was built using the standard homology parameters of Yasara.<sup>32</sup> Only *meso*-2,3-BDH (1GEG) was used as a template in order to preserve the position of catalytically important side chains.

Docking was done in the Yasara program with 100 docking runs using VINA and a minimum ligand RMSD of 1.5 Å. All residues were fixed except the important residues lining the active site, namely Ser138, Val139, Trp146, Tyr151, Lys155, Trp192 and the nicotinamide part of NADH. All docked compounds were visually inspected to determine the most probable catalytically active position. This binding mode was minimised with the NOVA force field to improve binding interactions with the protein.

## Acknowledgements

This study was financially supported by The Netherlands Organization for Scientific Research (NWO) under the framework of Technology Area TA-Biomass. We thank Martina Pohl and Dörte Rother (Forschungszentrum Jülich GmbH, IBG-1: Biotechnology, Jülich, Germany) for providing 1-phenyl-1,2-propanediol and 2-hydroxy-1-phenylpropan-1-one isomers and the enzymes for the synthesis of 1-hydroxy-1-phenylpropan-2-ones and for revising the manuscript.

## References

- 1 C. Palomo, M. Oiarbide and J. M. Garcia, *Chem. Soc. Rev.*, 2012, **41**, 4150–4164.
- 2 P. Hoyos, J. V. Sinisterra, F. Molinari, A. R. Alcantara and P. Dominguez de Maria, *Acc. Chem. Res.*, 2010, **43**, 288–299.
- 3 C. R. Unelius, B. Bohman, M. G. Lorenzo, A. Tröger, S. Franke and W. Francke, *Org. Lett.*, 2010, **12**, 5601–5603.
- 4 B. Plietker, *Tetrahedron: Asymmetry*, 2005, **16**, 3453–3459.
- 5 S. E. Schaus, B. D. Brandes, J. F. Larrow, M. Tokunaga, K. B. Hansen, A. E. Gould, M. E. Furrow and E. N. Jacobsen, *J. Am. Chem. Soc.*, 2002, **124**, 1307–1315.
- 6 P. P. Giovannini, O. Bortolini and A. Massi, *Eur. J. Org. Chem.*, 2016, **2016**, 4441–4459.
- 7 J. Kulig, R. C. Simon, C. A. Rose, S. M. Husain, M. Häckh, S. Lüdeke, K. Zeitler, W. Kroutil, M. Pohl and D. Rother, *Catal. Sci. Technol.*, 2012, **2**, 1580.
- 8 D. Kihumbu, T. Stillger, W. Hummel and A. Liese, *Tetrahedron: Asymmetry*, 2002, **13**, 1069–1072.
- 9 E. Celinska and W. Grajek, *Biotechnol. Adv.*, 2009, **27**, 715–725.
- 10 O. Bortolini, G. Fantin, M. Fogagnolo, P. P. Giovannini, A. Guerrini and A. Medici, *J. Org. Chem.*, 1997, **62**, 1854–1856.
- 11 E. Calam, E. Gonzalez-Roca, M. R. Fernandez, S. Dequin, X. Pares, A. Virgili and J. A. Biosca, *Appl. Environ. Microbiol.*, 2016, **82**, 1706–1721.
- 12 E. Calam, S. Porte, M. R. Fernandez, J. Farres, X. Pares and J. A. Biosca, *Chem.-Biol. Interact.*, 2013, **202**, 195–203.
- 13 C. Loderer and M. B. Ansorge-Schumacher, *RSC Adv.*, 2015, **5**, 38271–38276.
- 14 C. E. Paul, I. Lavandera, V. Gotor-Fernández, W. Kroutil and V. Gotor, *ChemCatChem*, 2013, **5**, 3875–3881.
- 15 M. Müller, D. Gocke and M. Pohl, *FEBS J.*, 2009, **276**, 2894–2904.
- 16 P. Domínguez de María, M. Pohl, D. Gocke, H. Gröger, H. Trauthwein, T. Stillger, L. Walter and M. Müller, *Eur. J. Org. Chem.*, 2007, **2007**, 2940–2944.
- 17 A. Petrenz, P. Domínguez de María, A. Ramanathan, U. Hanefeld, M. B. Ansorge-Schumacher and S. Kara, *J. Mol. Catal. B: Enzym.*, 2015, **114**, 42–49.
- 18 M. Kotik, A. Archelas and R. Wohlgemuth, *Curr. Org. Chem.*, 2012, **16**, 451–482.
- 19 K. Edegger, W. Stampfer, B. Seisser, K. Faber, S. F. Mayer, R. Oehrlein, A. Hafner and W. Kroutil, *Eur. J. Org. Chem.*, 2006, **2006**, 1904–1909.
- 20 M. Kurina-Sanz, F. R. Bisogno, I. Lavandera, A. A. Orden and V. Gotor, *Adv. Synth. Catal.*, 2009, **351**, 1842–1848.
- 21 P. Besse, J. Bolte, A. Fauve and H. Veschambre, *Bioorg. Chem.*, 1993, **21**, 342–353.
- 22 L. N. Monsalve, P. Cerrutti, M. A. Galvagno and A. Baldessari, *Biocatal. Biotransform.*, 2010, **28**, 137–143.
- 23 J. Zhang, S. Wu, J. Wu and Z. Li, *ACS Catal.*, 2015, **5**, 51–58.
- 24 A. Jakoblinert and D. Rother, *Green Chem.*, 2014, **16**, 3472–3482.
- 25 L. Zhang, Q. Xu, S. Zhan, Y. Li, H. Lin, S. Sun, L. Sha, K. Hu, X. Guan and Y. Shen, *Appl. Microbiol. Biotechnol.*, 2014, **98**, 1175–1184.
- 26 Evocatal GmbH, <http://www.biocatal.com/download.php?dl=adh380>, (accessed 16-12-2016, 2016).
- 27 M. Otagiri, G. Kurisu, S. Ui, Y. Takusagawa, M. Ohkuma, T. Kudo and M. Kusunoki, *J. Biochem.*, 2001, **129**, 205–208.
- 28 M. Otagiri, S. Ui, Y. Takusagawa, T. Ohtsuki, G. Kurisu and M. Kusunoki, *FEBS Lett.*, 2010, **584**, 219–223.
- 29 C. Filling, K. D. Berndt, J. Benach, S. Knapp, T. Prozorovski, E. Nordling, R. Ladenstein, H. Jörnvall and U. Oppermann, *J. Biol. Chem.*, 2002, **277**, 25677–25684.
- 30 J. Sambrook, E. F. Fritsch and T. Maniatis, *Molecular cloning: a laboratory manual*, Cold Spring Harbor Laboratory Press, New York, 3rd edn, 2001.
- 31 F. W. Studier, *Protein Expression Purif.*, 2005, **41**, 207–234.
- 32 E. Krieger and G. Vriend, *Bioinformatics*, 2014, **30**, 2981–2982.

